Background: This study explored the efficacy and safety of rituximab as treatment of clinical or molecular residual disease after autologous stem-cell transplantation (ASCT) in follicular lymphoma (FL).
introduction Follicular lymphoma (FL) is a B-cell lymphoma accounting for one-third of all newly diagnosed non-Hodgkin's Lymphoma (NHL) [1, 2] .
To improve the outcome of FL, different approaches have been tested: addition of immunotherapy (rituximab) to chemotherapy [3] [4] [5] [6] , myeloablative therapy followed by autologous stem-cell transplantation (ASCT) [7] [8] [9] [10] [11] , and more recently, rituximab maintenance treatment following induction with chemoimmunotherapy [12] .
The role for ASCT as a consolidation in first-line therapy has been investigated with discordant results [5, 10, 11, [13] [14] [15] . ASCT is an option for young patients with chemosensitive relapse or refractory FL [7, [16] [17] [18] . The main limitations of this treatment were secondary malignancies and disease recurrence [19] .
After ASCT, most relapses occur if complete response (CR) is not achieved or persistent molecular residual disease (MRD) is detectable. The t(14;18)-translocation that results in BCL2-IGH rearrangement can be detected by polymerase chain reaction (PCR) analysis in >90% of cytogenetically t(14;18)-positive FLs, providing an easily accessible marker for molecular disease monitoring [20] [21] [22] . MRD after ASCT is predictive for shorter progression-free survival (PFS) in FL [23] [24] [25] . It is reasonable to assume that any post-ASCT treatment capable of increasing CR or eradicating BCL2/IGH PCR-detectable residual disease would improve outcome.
Single-agent rituximab (Mabthera®) given as a 4-weekly course is an option, because it induces high CR and molecular responses rates in patients with FL having low tumor burden [26, 27] , or in patients with mantle cell lymphoma when given as preemptive treatment of molecular relapse after ASCT [28, 29] .
We report the final results of a prospective multicenter study testing a 4-weekly course of rituximab to eradicate clinical or molecular residual disease persisting 3 months after ASCT in patients with FL. Patients, aged 18-75 years, were required to have a histologically proven CD20+ follicular lymphoma of any grade, according to World Health Organisation (WHO) classification [1] , previously treated with high-dose therapy followed by ASCT [bone marrow (BM) or peripheral blood (PB) cells] as first-, second-, or third-line therapy and a detectable MRD 3 months after ASCT. The patients were divided into two groups according to the pattern of residual disease. Group A included patients with measurable residual disease on computed tomography (target lesions >1 and <3 cm); a BM involvement of ≤30% was accepted in this group. Group B was restricted to BCL2 informative patients with a complete clinical response but a molecular residual disease, e.g. BCL2-IgH rearrangement detectable by clono-specific (CS) PCR in PB and/or BM after ASCT. Other inclusion criteria were Eastern Cooperative Oncology Group performance status less than two, adequate renal and hepatic functions, absolute neutrophil count >1.0 × 10 9 /l, and platelets >50 × 10 9 /l without ongoing transfusional support. Patients were excluded if they had received more than three chemotherapy regimens before ASCT (rituximab as part of a cytoreductive therapy before ASCT was allowed), had symptomatic central nervous system lymphoma, and known active hepatitis B or C or HIV positivity. Patients were also excluded if they had a severe concomitant medical or psychiatric illness, other primary malignancy, or if they were pregnant or breastfeeding.
treatment
Within 3 weeks of baseline MRD assessment and 3 months (±21 days) from ASCT, rituximab (Mabthera®, Roche, France) was given at a weekly dose of 375 mg/m² by intravenous infusion, for 4 consecutive weeks. Premedication with acetaminophen and dextrochlorpheniramine was systematically given, steroids were allowed at physician's discretion before the first infusion only. Safety was assessed using the National Cancer Institute Common Toxicity Criteria grading system, version 2. In case of grade 3-4 adverse events, the study treatment was interrupted and resumed at the same dose after it resolved to grade ≤1 toxicity. If the same event with the same severity occurred again, the study treatment was discontinued. No other antilymphoma therapy or i.v. immunoglobulins were allowed during the study.
study end points
The primary end point was response rate to rituximab treatment assessed 50 days (d50) after the first rituximab administration and defined as: (i) the proportion of patients with clinically detectable residual disease after ASCT (group A) achieving either CR or PR according to WHO criteria (imaging was reviewed by an independent committee); (ii) the proportion of patients with MRD after ASCT (group B) achieving a molecular response, defined as the conversion from a PCR-positive status (PCR-detectable BCL2/IGH levels) at baseline to a PCR-negative status (PCR-undetectable BCL2/IGH levels). Molecular relapse was defined as reversion to a PCR-positive status in two consecutive samples. Patients with a PCR-positive sample at baseline were deemed nonassessable for molecular response if no sample was collected at d50 (missing data).
Secondary efficacy end points included clinical and molecular responses evaluated during a scheduled staging/molecular assessment, 3-year PFS, and 3-year overall survival (OS).
clinical evaluation
The baseline evaluation was carried out 3 months (±21 days) after ASCT. Disease status was determined by physical examination, computed tomography of the neck, chest, abdomen, and pelvis, and BM biopsy. Laboratory tests included complete blood counts (CBC), serum chemistry panel, serum immunoglobulin levels, lactate dehydrogenase, β2-microglobulin levels, and urinalysis. Monitoring included physical examination, CBC, and serum chemistries before each rituximab infusion. Patients were restaged at d50 and then at 6, 12, 24, and 36 months after the first rituximab infusion, or at disease progression. BM biopsy was controlled at 12 months for patients with baseline involvement and at 36 months for all patients.
PCR methods and molecular monitoring of BCL2/ IGH rearrangement molecular response criteria All samples were centralized in the Department of pathology and CIGH/ CNRS, University Hospital of Purpan, Toulouse, France.
The sequence of the BCL2/IGH junction region was characterized for each patient using fragments amplified from sample collected at primary diagnosis (fresh or frozen lymph node biopsy specimens or massively involved PB or BM). From each BCL2/JH sequence, a 20-24 mer oligonucleotide complementary to this junction was synthesized and used first as a CS primer for the detection of MRD by two-stage PCR amplification [30] . The second PCR amplification was a seminested procedure using the CS primer in conjunction with major breakpoint region R3+ (MBRR3+) and MC8 or Eμ/01 for the classical PCR and the long-distance PCR, respectively [31, 32] . A reproducible sensitivity of 10
was routinely obtained with this CS-PCR assay. For patients with a clonal BCL2/JH rearrangement detected at diagnosis, the baseline assessment of MRD was done 3 months (±21 days) after ASCT. Subsequent PB and BM samples were obtained at day 50 and 6 months after rituximab treatment, and then every 6 months for PB or every year for BM until 3 years of follow-up. Each baseline and follow-up sample was tested five times. relapsed FL. An overall response rate (ORR) of 48% was observed in relapsed FL after rituximab [33] . The two-sided type I error was set to 10%. The inclusion of 34 patients would allow a preliminary estimation of the response rate with a precision of 15% and a 90% confidence interval (CI). Therefore, 40 patients were planned.
The ORR was described using the exact binomial 90% CI. The time-toevent parameters were analyzed according to the Kaplan-Meier method [34] . The duration of response was defined as the time between the first documented clinical or molecular response and the clinical evidence of disease progression at 3-year, reversion to a PCR-detectable status (in group B only) or death. Time to clinical progression or relapse was the time between the first dose of the study treatment and the date of tumor progression. The 3-year OS was the time between the first infusion of the study treatment and death from any cause. results
patients' characteristics
Forty patients were included, 14 patients in group A and 26 in group B. One patient with negative BCL-2 status at baseline in group B was excluded for protocol violation. One patient discontinued treatment after three rituximab infusions due to severe rhinitis but was followed up until study end. Thus, 39 patients having received at least one dose of the study treatment were analyzed for response and safety. The median time between transplant and inclusion visit was 2.86 months (range 1.3-3.8).
Patient demographics and baseline characteristics are summarized in Table 1 . Median age was 48 ; median number of prior chemotherapy regimens was 2 (range 1-3). ASCT was given as a first-line consolidation therapy in 12 patients and as part of a salvage therapy in 27 patients. Importantly, only five patients (two in group A and three in group B) were treated with rituximab before ASCT.
In group A, all the patients were in PR after ASCT. The median number of residual lesions at baseline was 1 (range 1-5), all documented on CT scan.
In group B, all had PCR BCL2-positive status before ASCT and remained positive after ASCT. In these 25 patients, breakpoints occurred in the MBR in 21 cases (including one long-MBR rearrangement) and in the minor cluster region (mcr) in four cases (including two long-mcr).
efficacy clinical and molecular response. In group A, at day 50 postrituximab infusion, 2/14 patients achieved a CR and 3/14 patients a PR for an ORR of 36% (Table 2 ), whereas 8/14 patients had stable disease and one patient experienced disease progression. The clinical response rate increased to 71% (n = 10) at 6 months, due to five delayed responses, then remained unchanged up to 36 months (Table 3) . Nine CRs were observed in this group of 14 patients (CR rate of 64%). The median time to response was 5.7 months (range: 1.6-6.3).
In group B, at day 50, 12/23 assessable patients achieved a molecular response for an ORR of 52% (90% CI 34-70), 11 patients remained PCR-positive and 2 patients were nonassessable (informative BM sample positive at baseline, but missing data at d50). Molecular responses increased over time: two molecular responses occurred at 6 months, one at 12 months, and four between 18 and 36 months. Thus, overall 19 of 25 patients achieved a molecular response during follow-up, for an overall best molecular response of 76% (90% CI 58-89) ( Table 2) . Of the 19 molecular responders, 11 (58%) remained PCR-negative 36 months after rituximab, whereas 7 patients had molecular relapse at a median time of 18 months (range: d50 to 18 months) (supplementary Figure S2 , available at Annals of Oncology online). outcome according to clinical or molecular response. In group A, the 3-year PFS was 62% (see Figure 1A) . None of the 10 responders experienced disease progression during the study.
In group B, overall, median clinical 3-year PFS was not reached ( Figure 1B) . Importantly, the 11 patients who became persistently PCR-negative remained in clinical CR 36 months after rituximab. By contrast, clinical relapse occurred in eight patients including four of the six patients who remained persistently PCR-positive and four of the eight patients with molecular relapse. In these latter four patients, molecular relapse preceded clinical relapse by at least 12 months.
Thus, median PFS of patients who achieved durable complete molecular response was not reached, whereas median PFS of patients who did not achieve molecular response or had molecular relapse was 1.6 and 2.7 years, respectively (P = 0.0095). At the end of the trial, all the patients were alive.
safety
The most frequent AEs during the study treatment (i.e. from the first administration of the study treatment until 28 days after the last treatment) were mild to moderate acute reactions, including rhinitis in 18% of patients, pharyngitis in 10%, nausea and arthralgia in 8% each ( Table 4 ). The most frequent events occurring after the treatment period were herpes zoster and pharyngitis (15% each), and neutropenia (13%). Six patients (15%) experienced grade 3 or 4 AEs deemed related to rituximab. Grade 3-4 neutropenia occurred in one patient (2.5%) during rituximab treatment and four (10%) patients within 3 months of the last dose of rituximab. None of these patients had a febrile neutropenia. All the patients recovered neutrophil counts >1.0 × 10 9 /l by 9 months of follow-up. Grade 3-4 thrombocytopenia was observed in one patient during treatment and in one patient during follow-up, at 18 months. All the patients had platelet counts >100 × 10 9 /l at M24. There were no clinically significant changes in median IgA, IgM, or IgG levels. No patient withdrew from the study for adverse events, and no death was reported during the study.
discussion
In this prospective study, we show that 4 consecutive onceweekly doses of rituximab given 3 months after ASCT yielded high response rates in FL patients with clinical residual disease (ORR 71% including 64% CR) or molecular residual disease (ORR 76%). All clinical responses (n = 10) and 58% (11/19) of the molecular responses were durable at the latest follow-up of 36 months after ASCT.
Of particular interest was the very good outcome without any clinical relapse of the 11 patients achieving a persistent molecular response (median PFS not reached) whereas PFS Annals of Oncology original articles was significantly lower for patients with transient or no molecular response 1.6 and 2.7 years, respectively (P = 0.0095). Our results on a larger number of patients with FL confirm previous reports on the efficacy of rituximab given as a treatment of residual disease after ASCT [35] [36] [37] [38] . Brugger et al. [36] reported a molecular response after four doses of rituximab in all nine patients with either FL or Mantle cell Lymphoma who were PCR-positive after ASCT. Another report on 27 patients including 12 FL demonstrated that monthly rituximab infusions administered as maintenance therapy for a median of 10 months after ASCT was feasible and well tolerated with three patients who were PCR-positive after ASCT achieving molecular response after rituximab maintenance [38] . Our efficacy results and the strong predictive value of molecular response are in keeping with those obtained with rituximab given as a treatment of molecular residual disease after conventional chemotherapy [27, 29, 39, 40] or in combination with induction chemotherapy [29, 40] . However, the present study is the first clearly showing a correlation between molecular remissions achieved with rituximab and an improved clinical outcome in the specific setting of MRD treatment after ASCT for patients with FL. In-depth comparison of the prognostic significance of PCRdetectable molecular disease between studies is difficult given the different PCR methodologies. Moreover, some PCR techniques such as conventional nested PCR are unable to distinguish malignant cells from possible t(14;18)-bearing nonmalignant cells [41, 42] . When this trial was designed in 1999, we choose to enhance the specificity of nested PCR by using a CS t(14,18) junctional sequence primer in the first round of our nested PCR [30] . In spite of its high sensitivity of 10
, this CS PCR technique accurately predicted PFS in all the patients in continued molecular response during 3 years after rituximab. Conversely, 6 of 14 patients who either failed to achieve molecular response or had molecular relapse did not experience clinical relapse, underlining the limited prognostic value of this technique in case of positive PCR findings during follow-up. Nowadays, we would use real-time quantitative PCR, as huge progress has been made for the standardization of this technique that achieves a high sensitivity without the risk of contamination of the nested PCR. This quantitative PCR most probably would have helped us improve prediction of clinical recurrence in patients with late conversion to a PCR-negative status, persistently PCR-positive tests, or molecular relapse.
Rituximab combined with chemotherapy followed by 12 infusions of rituximab maintenance is now considered the standard of care in first-line therapy for FL [12] . Both ASCT consolidation and rituximab maintenance for a total of eight infusions are valuable options in the relapse setting [11, 16, 43, 44] . Recently, a randomized study in patients with relapsed follicular NHL undergoing a high-dose therapy conditioning with BEAM showed that periautograft rituximab (in vivo purging and 2 years maintenance postautograft) provides a superior PFS compared with no rituximab [45] . Still, it is noteworthy that a short course of four infusions of rituximab was shown to be highly efficient on MRD in three studies in FL including ours [27, 36] , a finding that raises the question of the optimal amount of rituximab maintenance after ASCT in the first place, but also more broadly postinduction chemotherapy. Another open question relates to the value of molecular residual disease assessment as a surrogate marker to drive decisionmaking on the duration of rituximab maintenance now that rituximab is routinely given as part of first-line therapy. original articles
Annals of Oncology
Rituximab in vivo activity against FL depends on natural killer (NK) cells and monocytes that are the main effectors of antibody-dependant cellular cytotoxicity (ADCC) [46] [47] [48] . The recovery of NK cell counts obtained during the first months after ASCT [28, [49] [50] [51] [52] and the observation that cytolytic functions could be increased after ASCT [53, 54] may have contributed to the high efficacy of rituximab when used as a single-agent after ASCT, as evaluated here. Furthermore, given the preserved ADCC after ASCT, other monoclonal antibodies with increased ADCC that are under development might be considered in this indication [55] . Finally, both clinical and molecular response rates improved over time, reflecting the progressive clearance of the neoplastic clone. The existence of true delayed responses >6 months after rituximab is consistent with previous reports [27, 36] and consistent with recent data suggesting a vaccinal effect of rituximab [47, 56, 57] .
The rate of patients with grade 3-4 neutropenia during and after treatment (13%) was higher than the rate of neutropenia reported in two phase III studies with rituximab in maintenance (4% grade 3-4 in the Prima study and 10.8% all grades in the EORTC 20981 study) [12, 44] . Our patients did not develop any infection during these neutropenic episodes.
In conclusion, our study provides a background for the use of a short course of rituximab in case of persistent residual FL disease after ASCT. Giving four once-weekly doses of rituximab, 3 months after ASCT was safe with no unexpected toxicity, and the rate of infection was low. Median levels of IgG and IgM were not significantly modified during or after treatment. Continued molecular responses assessed by a highly sensitive and CS PCR technique were correlated to an excellent clinical outcome. Although the current follow-up is short in the context of FL, these results are very encouraging in patients who are considered to be at high risk of short-term clinical recurrence in view of their persistent MRD after ASCT.
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